B
Bull
Bull · 25%RGC
$19.32
Scenario price
$9.520
+1.656 (+17.39%)At close
Loading chart…
- High
- 11.120
- Open
- 7.980
- VWAP
- 9.45
- Volume
- 1.92M
- Mkt Cap
- 45.81M
- Low
- 7.720
- Amount
- 18.13M
- EV/EBITDA, TTM
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
AI analysis of Regencell Bioscience Holdings Ltd (RGC)
HoldRegencell Bioscience Holdings Ltd is currently priced at 7.35, with a recent RSI of 66.989 indicating it is approaching overbought territory. The stock has seen a 5-day change of +7.77%, but it remains down 64.22% year-to-date, suggesting significant long-term challenges. While there was a notable surge of 35% amid a short squeeze, the overall trend shows a decline of 59.14% over the past year, indicating that caution is warranted. The main risk is the negative P/E ratio of -633.62, reflecting ongoing financial difficulties.
Analyst Ratings (15)
Buy
9 Buy
5 Hold
1 Sell
Current: 9.52
Low
—
Average
—
High
—
Valuation Metrics
The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for RGC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC FAQ — answered by Alphio AI
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is currently priced at 7.35, with a recent RSI of 66.989 indicating it is approaching overbought territory. The stock has seen a 5-day change of +7.77%, but it remains down 64.22% year-to-date, suggesting significant long-term challenges. While there was a notable surge of 35% amid a short squeeze, the overall trend shows a decline of 59.14% over the past year, indicating that caution is warranted. The main risk is the negative P/E ratio of -633.62, reflecting ongoing financial difficulties.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.